Quantum Cyber N.V.
QUCY Nasdaq Pharmaceutical Preparations Financials FY2024–FY2025
What Quantum Cyber N.V. does
No business description yet.
- Legal name
- Quantum Cyber N.V.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Accession · CIK
- 0001213900-26-037676
0001874252
Revenue and margins
Quantum Cyber N.V. had $0.5M of revenue in fiscal 2025, down 39.9% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$11.0M in fiscal 2025, −2,044.5% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Quantum Cyber N.V. returned — to shareholders in fiscal 2025. The diluted share count rose 508.4%.
Balance sheet
Cash, debt and the ratios that show how comfortably Quantum Cyber N.V. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $6.2M | $0.9M |
| Debt incl. finance leases | $1.0M | $1.0M |
| Debt / equity | 0.2x | 1.5x |
| Interest coverage | −19.9x | −43.2x |
| Current ratio | 1.3x | 0.9x |
| Quick ratio | 1.2x | 0.9x |
| Total assets | $13.5M | $5.3M |
| Total liabilities | $7.5M | $4.7M |
| Shareholders' equity | $6.0M | $0.6M |
| Net debt (− = net cash) | −$5.2M | $0.1M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | ✕ |
| Current ratio rose | — | ✕ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | ✓ |
| Revenue rose relative to assets | — | ✓ |
| F-score | — / 3 | 3 / 9 |
| Accruals ratio | −31.6% | −55.6% |
| Altman Z'' | −29.03 | −84.99 |
2 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $0.9M | $0.5M |
| Gross profit | $0.6M | $0.4M |
| Research and development | $5.7M | $4.9M |
| Operating income | −$18.8M | −$16.1M |
| Interest expense | $0.9M | $0.4M |
| Pretax income | −$21.6M | −$16.2M |
| Net income | −$21.6M | −$16.2M |
| Diluted EPS | −$21.91 | −$2.70 |
| Diluted shares | 0.00B | 0.01B |
| Cash flow | ||
| Cash from operations | −$17.3M | −$11.0M |
| Capital expenditure | $0.1M | $0.0M |
| Free cash flow | −$17.4M | −$11.0M |
| Depreciation and amortization | $0.7M | $0.6M |
| Stock-based compensation | −$0.1M | $1.5M |
| Balance sheet | ||
| Cash and short-term investments | $6.2M | $0.9M |
| Total debt | $1.0M | $1.0M |
| Current assets | $8.0M | $4.2M |
| Current liabilities | $6.2M | $4.7M |
| Inventory | $0.4M | $0.2M |
| Property and equipment, net | $1.4M | $1.1M |
| Intangible assets | $3.0M | $1.1M |
| Total assets | $13.5M | $5.3M |
| Total liabilities | $7.5M | $4.7M |
| Shareholders' equity | $6.0M | $0.6M |
| Margins | ||
| Gross margin | 64.3% | 72.6% |
| Operating margin | −2,099.9% | −3,004.9% |
| EBITDA margin | −2,022.0% | −2,890.2% |
| Net margin | −2,416.0% | −3,018.2% |
| FCF margin | −1,950.1% | −2,044.5% |
| Returns | ||
| Return on capital | −1,889.3% | −1,797.3% |
| Return on capital employed | −256.5% | −2,515.4% |
| Return on equity | −360.1% | −488.3% |
| Return on assets | −160.0% | −172.2% |
| Return on tangible equity | −724.7% | — |
| Growth | ||
| Revenue growth | — | −39.9% |
| Share count change | — | 508.4% |
| Financial health | ||
| Debt / equity | 0.2x | 1.5x |
| Interest coverage | −19.9x | −43.2x |
| Current ratio | 1.3x | 0.9x |
| Quick ratio | 1.2x | 0.9x |
| Capital allocation | ||
| Capex / revenue | 11.7% | 0.2% |
| Stock comp / revenue | −7.1% | 274.1% |
| Quality scores | ||
| Piotroski F-score | — | 3.0 |
| Altman Z'' | −29.0 | −85.0 |
| Accruals ratio | −31.6% | −55.6% |
Source: SEC EDGAR XBRL filings (CIK 0001874252). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.